

Author Correction: Utilization of peginterferon- β -1a in the real-world practice for relapsing-remitting multiple sclerosis

M. MOCCIA, L. SANTONI, I. VACCARI, G. AFFINITO, D. CALIENDO, F. RUBBA, R. LANZILLO, M. TRIASSI, V. BRESCIA MORRA, R. PALLADINO

Multiple Sclerosis Unit, Policlinico Federico II University Hospital of Naples, Naples, Italy

Correction to: European Review for Medical and Pharmacological Sciences 2024; 28 (1): 411-418. DOI: 10.26355/eurrev_202401_34930-published online on January 16, 2024.

After publication, the authors have applied some corrections to the galley proof:

- In the Patients and Methods section of the abstract, “National Health System” is corrected to “National Health Service”.
- In the Conclusions section of the abstract, “SC PEG-IFN- β -1a and IFN- β -1a” is corrected to “PEG-IFN- β -1a and SC IFN- β -1a”.
- In the Population section, the study period “January 1st 2015 to December 31st 2019” was not reported; therefore, this specification has been added to the text.
- The legend of Figure 1 was wrongly reported as the same as Table I. The correct title of Figure 1 is “Study flow diagram”.
- Under Tables I, II, and III, “interferon beta 1a IFN- β -1a” is corrected to “interferon beta 1a (IFN- β -1a)”.
- In Table III, “CS Glatiramer acetate” is corrected to “SC Glatiramer acetate”.
- In the Conclusions section, “SC IFN- β -1a SC” is corrected to “SC IFN- β -1a”.
- The funding section has been amended as follows: “This study was sponsored by Biogen Italia (Milan, Italy).”

There are amendments to this paper. The Publisher apologizes for any inconvenience this may cause.